Repare Therapeutics Inc. (RPTX) Thursday said it received $40 million milestone payment from Roche under its agreement with the company for the development and commercialization of camonsertib.
The milestone payment was triggered by dosing of the first patient with camonsertib in Roche's Phase 2 TAPISTRY study.
TAPISTRY is a Phase 2 study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy in participants with solid tumors.
As per the deal with Roche, Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.